Benefits outweigh risks in most scenarios, FDA review says of Pfizer vaccine for children | TheHill - The Hill
A review by the Food and Drug Administration (FDA) indicated on Friday that the Pfizer-BioNTech’s COVID-19 vaccine provided more benefits to children in most scenarios than possible risk, the latest sign that health agencies could give the green light on a vaccine for children as young as 5 years old in the coming weeks, The Washington Post reported.An FDA review found that a two-dose regimen of the Pfizer vaccine for children provided more benefits to children than risks in three of four scenarios that the agency considered. .The FDA noted that there could be the risk of more pediatric hospitalizations due to myocarditis stemming from the vaccine than COVID-19 in the scenarios of lower levels of COVID-19 transmission, but noted “the overall benefits of the vaccine may still outweigh the risks under this lowest incidence scenario,” according to the newspaper.